James Stambaugh, VP Clinical Affairs at Intersect ENT, Inc. (XENT), sold 8,343 shares at $25.50 ($213K) on 2015-04-01, disclosed to the SEC on 2015-04-02.
Scheduled sale ($213k) by VP Clinical Affairs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| XENT | SELL | 2016-07-19 | $77K | — | Filing → |
| XENT | SELL | 2016-06-14 | $7K | — | Filing → |
| XENT | SELL | 2015-07-21 | $366K | — | Filing → |